VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the deltaF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote deltaF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1].
Molekulargewicht:
510.65
Reinheit:
99.15
CAS Nummer:
[815592-21-3]
Formel:
C27H34N4O4S
Target-Kategorie:
CFTR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
